Jonathan Rothberg, founder and independent director of Butterfly Network, sold approximately 3.1 million Class B shares at $6.64 each, totalling $20.7 million, according to an SEC filing. The sale was conducted under a Rule 10b5-1 trading plan adopted in March 2026 for estate planning purposes. Following the transaction, Rothberg directly holds roughly 106,000 shares and indirectly controls about 19.6 million shares through various entities including family trusts. The sale occurred as Butterfly Network shares returned 263% over the preceding 12 months. Butterfly Network develops portable ultrasound imaging devices that connect to smartphones and tablets. The company has a market capitalisation of $1.8 billion, with trailing twelve-month revenue of $102.9 million and a net loss of $75.8 million.

Butterfly Network CEO Joseph Devivo sold nearly 212,000 shares of Class A Common Stock on 20 July 2026, valued at $1.4 million, according to an SEC Form 4 filing. The transaction was automatically executed to cover tax withholding obligations from vesting restricted stock units. Following the sale, Devivo retains 7,672,046 shares worth $51.33 million at the 20 July market close. The Burlington-based medical device company's shares have surged 260% over the past year. Butterfly Network designs portable ultrasound imaging devices, including the Butterfly iQ series, which connect to smartphones and tablets. The firm reported trailing-twelve-month revenue of $102.9 million and holds a market capitalisation of $1.8 billion, despite posting a net loss of $75.8 million.

Butterfly Network has launched its Butterfly iQ+ and iQ3 handheld ultrasound devices in Brazil through authorised distribution partners, marking a significant expansion into Latin America's largest medical device market. The move follows the company meeting Brazil's regulatory and certification requirements. Despite the announcement, BFLY shares fell 3.2% yesterday, though the stock has climbed 102.1% year to date, outperforming both the industry and S&P 500. The company currently holds a $2.02 billion market capitalisation. Brazil's healthcare system, particularly in remote areas, presents opportunities for Butterfly Network's portable ultrasound technology. The devices use proprietary Ultrasound-on-Chip technology and work with iOS and Android devices, enabling whole-body imaging with a single handheld unit. The semiconductor-based design offers a more accessible alternative to conventional ultrasound systems.